Drugs / Interferon-beta
Interferon-beta
also known as
Recombinant Interferon Beta · Avonex (beta interferon) · beta interferon · Betaseron (beta interferon) · Extavia (beta interferon) · IFN beta · IFN β-1a · IFN-β · +3 more
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02584829 | Nov 2015 → Dec 2018 | — | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01758458 | Feb 2013 → May 2016 | cutaneous neuroendocrine carcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00789685 | Feb 2009 → Sep 2011 | acute lung injury, acute respiratory distress syndrome | Faron Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01171209 | Jul 2010 → Jun 2011 | multiple sclerosis | Melinda Magyari | Completed | No outcome recorded |
| Phase 2 | NCT00085306 | Apr 2004 → Oct 2007 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04324463 | Apr 2020 → Dec 2022 | severe acute respiratory syndrome | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01753570 | Dec 2012 → Oct 2015 | chronic hepatitis C virus infection | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00344253 | Mar 2006 → Mar 2011 | intermediate uveitis, macular retinal edema, multiple sclerosis | Heidelberg University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03535298 | Jan 2019 → Jul 2027 expected | relapsing-remitting multiple sclerosis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004450 | Aug 1998 → Nov 2000 | adrenoleukodystrophy | FDA Office of Orphan Products Development | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02903537 Background | Jul 2017 → Dec 2023 | chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis | Germans Trias i Pujol Research Institute | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06715605 Comparator | Apr 2025 | multiple sclerosis | University Hospital, Antwerp | Withdrawn | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon beta | “Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.” NCT06715605 ↗ |
| Known as | Avonex (beta interferon) | “Avonex (beta interferon)” NCT03535298 ↗ |
| Known as | beta interferon | “Betaseron (beta interferon)” NCT03535298 ↗ |
| Known as | Betaseron (beta interferon) | “Betaseron (beta interferon)” NCT03535298 ↗ |
| Known as | Extavia (beta interferon) | “Extavia (beta interferon)” NCT03535298 ↗ |
| Known as | IFN beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01753570 ↗ |
| Known as | IFN β-1a | “This was a phase I/II open-label study to assess the safety, tolerability and preliminary efficacy of FP-1201 (IFN β-1a) in the treatment of patients with ALI and ARDS.” NCT00789685 ↗ |
| Known as | IFN-β | “A major problem in the treatment of multiple sclerosis (MS) patients with interferon-beta (IFN-β) is the development of neutralising antibodies (NAbs).” PMID 25877635 ↗ Dec 2012 |
| Known as | interferon-beta-1a | “The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.” PMID 24503265 ↗ Dec 2013 |
| Known as | Plegridy (beta interferon) | “Plegridy (beta interferon)” NCT03535298 ↗ |
| Known as | Rebif (beta interferon) | “Rebif (beta interferon)” NCT03535298 ↗ |
| Known as | Recombinant Interferon Beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02584829 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant interferon beta” NCT00085306 ↗ |
| Route | Subcutaneous | “interferon beta by subcutaneous injection” NCT00004450 ↗ |